Navigation Links
Shanghai ChemPartner Is Pleased to be Part of Agios' Groundbreaking Cancer Research
Date:12/9/2009

SHANGHAI, Dec. 9 /PRNewswire-Asia/ -- Shanghai ChemPartner Co., Ltd. (ChemPartner) a wholly owned subsidiary of ShangPharma Corporation, today announced that ChemPartner scientists are pleased to have been involved in recent groundbreaking cancer research from Agios Pharmaceuticals through the companies' ongoing partnership. This breakthrough discovery by Agios scientists was recently published online on November 22nd by Nature in an article entitled "Cancer-associated IDH1 mutations produce 2-hydroxyglutarate (2HG)".

"The important discovery by Agios and the publication of the Nature article solidifies Agios' leading role in cancer metabolism," Michael Hui, founder and CEO of ChemPartner commented. "ChemPartner has been providing integrated drug discovery research support in the areas of protein science, HTS, enzymology, cell biology, in vivo pharmacology, and DMPK to Agios' innovative R&D programs in the emerging field of cancer metabolism. We congratulate the great achievement by Agios scientists and are also proud of the contribution we made to this partnership. This also demonstrates the quality of scientific work performed at ChemPartner. We look forward to continuing to help Agios advance its drug discovery programs and pipelines."

"The flexibility and expertise of our partners enabled Agios scientists to make this discovery very quickly," said Michael Su, VP Drug Discovery and Interim CSO at Agios Pharmaceuticals. "This new understanding of IDH1 mutants has opened up a new strategy for treating certain forms of cancer. ChemPartner's scientific capabilities will facilitate the continued progress of our drug discovery programs and shorten the time to bring new cancer therapeutics to patients."

About Shanghai ChemPartner

Founded in 2003, Shanghai ChemPartner Company Ltd. (ChemPartner) is one of the leading contract research organizations providing medicinal chemistry, discovery biology, pharmacology, DMPK, toxicology, process R&D, analytical development, formulation and contract manufacturing services to over 120 pharmaceutical and biotech companies in the world. ChemPartner currently has a team of over 1,000 scientists including over 90 senior scientific leaders with extensive industry experiences gained from leading global pharmaceutical and biotech companies.

Further information is available at http://www.shangpharma.com .

SOURCE Shanghai ChemPartner Co., Ltd.


'/>"/>
SOURCE Shanghai ChemPartner Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. American Scientific Resources Inc. Opens Shanghai Location
2. Sinovac Receives Purchase Order from Shanghai Government to Supply Hepatitis A Vaccine Healive(R)
3. UNT Health Science Centers Groundbreaking Research Applied to Protecting Brain After Traumatic Injury
4. Stand Up To Cancer Awards $73.6 Million for Novel, Groundbreaking Cancer Research
5. Lake Hospital System Receives $60,000 Grant for Groundbreaking Music Therapy Study
6. Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinsons Disease
7. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
8. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
9. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
10. For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain
11. New FDA Approved Breast Cancer Screening Tool
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... April 19, 2017 Global Surgical Drainage Device ... tubes used to remove excess liquid and air. The ... urine, bile or lymph. Surgical drains are used in ... as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. ... to prevent accumulation of fluid e.g. blood or pus. ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group ... it is developing at Conejo Spectrum Business Park ... to Atara Biotherapeutics, Inc. , a biopharmaceutical ... and life-threatening diseases that have been underserved by ... T-cell therapies for cancer, autoimmune and infectious disease. ...
Breaking Medicine Technology:
(Date:4/25/2017)... Richmond, BC (PRWEB) , ... April 25, 2017 , ... ... patients from Richmond, BC, who live with dental fear and require sedation to receive ... anxiety at ease during various procedures, from hygienic cleanings to oral surgery, at ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... they rely on contracted partners to help with process innovation in drug formulation ... drug formulation experience along with state-of-the-art analytical equipment in support of their development ...
(Date:4/25/2017)... MN (PRWEB) , ... April 25, 2017 , ... Buyers ... and recreational users to dispensaries and head shops –can’t help but be heartened by ... for the tell-tale cannabis odor aptly described as “skunk smell.” At last they ...
(Date:4/25/2017)... ... 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley ... in Writing, set to publish in summer 2017. , Dr. Bobrow, MD, FACEP, ... Arizona College of Medicine. He also serves as Medical Director for the Bureau of ...
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., designer, developer, and ... partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), a charitable organization ... of complex spine deformity cases, particularly in children. , GSO’s focus is to ...
Breaking Medicine News(10 mins):